Skip to main content

Table 3 Clinical data at baseline and at 3 months

From: Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis

 

Responders

Non-responders

 

Subset 1

Subset 2

Subset 1

Subset 2

 

Baseline

3 monthsa

Baseline

3 monthsa

Baseline

3 monthsa

Baseline

3 monthsa

Morning stiffness (minutes)b

245 ± 126c

35 ± 24.5c

210 ± 81

58 ± 70.2c

179 ± 159

66.4 ± 86c

133 ± 84

62 ± 67.6c

DAS28 b

6.4 ± 1.0

4.2 ± 0.9c

6.2 ± 0.7

3.8 ± 0.6c

5.7 ± 0.8

5.3 ± 1.0

5.5 ± 1.0

4.9 ± 1.0c

Pain (0–100 mm VAS)

59.3 ± 20.3

29.3 ± 9.3c

62.5 ± 15.5

31.3 ± 14.5c

69.3 ± 13.1

54.1 ± 22.1

60.9 ± 11.4

40.6 ± 18.4c

ESR (mm/hour)

44 ± 26.2

27 ± 20.3c

27.2 ± 15.7

11.3 ± 5.2c

35.7 ± 25.7

28.3 ± 15.3

24.1 ± 11.5

27.8 ± 19.2

CRP (mg/l)b

42 ± 29.8

20 ± 15.7c

28.6 ± 19.7

6.2 ± 6.1c

18.5 ± 12.7

13 ± 8.2

15.8 ± 15.6

11 ± 7.3

HAQ score (0–3 scale)

1.6 ± 0.4

0.9 ± 0.5c

1.8 ± 0.7

1.2 ± 0.7c

1.6 ± 0.4

1.2 ± 0.3

1.5 ± 0.4

1.5 ± 0.4

  1. Values are mean ± standard deviation. aResponse assessed just before the fourth infliximab/methotrexate infusion. Significant differences between groups are as follows: bdifference between all responders versus non-responders at baseline (0.03 <p < 0.05, Mann and Whitney's test); other comparisons were non-significant (p = 0.58); cDifference at baseline versus 3 months in this subset (p < 0.05, paired Wilcoxon's test). CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; VAS, visual analogue scale (patient's assessment of pain).